Michael Baranello

Title: Michael Baranello: Innovator in Alkaline Phosphatase Research

Introduction

Michael Baranello is a notable inventor based in Boston, MA. He has made significant contributions to the field of biochemistry, particularly in the development of polypeptides that have therapeutic applications. His work focuses on addressing bone mineralization disorders, which can have profound effects on patients' health.

Latest Patents

Michael Baranello holds a patent for "Alkaline phosphatase polypeptides and methods of use thereof." This patent features polypeptides that include soluble alkaline phosphatases, mutants, fragments, and fusion proteins. These innovations are aimed at treating bone mineralization disorders, such as hypophosphatasia (HPP), and alleviating associated symptoms. The polypeptides include a soluble alkaline phosphatase (sALP) or a fragment derived from a naturally occurring alkaline phosphatase (ALP).

Career Highlights

Baranello is currently employed at Alexion Pharmaceuticals, Inc., where he continues to advance his research in the field. His work has the potential to impact the treatment of various bone-related disorders, showcasing his commitment to improving patient outcomes through innovative solutions.

Collaborations

Throughout his career, Michael has collaborated with esteemed colleagues, including Walter C. Voegtli and Keith Bouchard. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic approaches.

Conclusion

Michael Baranello's contributions to the field of alkaline phosphatase research exemplify the impact of innovation in medicine. His patent and ongoing work at Alexion Pharmaceuticals, Inc. highlight his dedication to addressing critical health issues.